In earlier studies, we noted that systemic administration of a low dose (30 μg) agonistic anti-CD40 antibody did not achieve the same anti-tumor efficacy as a local administration at the tumor site, illustrating the reliance on antigen shedding of the tumor for efficacy18. This evidence concerns the gene CD40 and neoplasm.